Covid-19 Therapeutic Prospects: Cardiotoxicity Concerns

Olawale Adeyemi, BS, MD*

Xavier University School of Medicine, Aruba

*Corresponding author: Olawale Adeyemi, BS, MD, Xavier University School of Medicine, 23 Santa Helenastraat, Oranjestad, Aruba

There has been extensive research on developing a treatment regimen for COVID-19. Coadministering Chloroquine and Azithromycin have shown promising results in infected people. However, these medications have a peculiar side effect; QT prolongation. Physicians should be aware of the populations taking them and routine EKGs are recommended in these candidates.

Since December 2019, there was an outbreak of a novel coronavirus disease (COVID-19), which was first reported in Wuhan, China. However, the spread has taken on pandemic proportions that have affected several countries across the globe in just a matter of weeks with the figures currently rising. Unfortunately, to date there are no vaccines or medicines approved for this novel infection. However, numerous clinical trials are being launched worldwide to test coronavirus treatments that include some drug repositioning and even repurposing for COVID-19. In a recent trial with patients on COVID-19 treatment [1], 100% of patients treated with hydroxychloroquine in combination with the macrolide antibiotic azithromycin were cured in comparison with 57.1% in patients treated with hydroxychloroquine alone, and 12.5% in the control group. In recent years, there has been researching on the antiviral properties of both medications. Chloroquine and Hydroxychloroquine have been used in the treatment of HIV with mixed results [2]. Azithromycin is active in vitro against Zika and Ebola viruses [3, 4]. The ability of these drugs to inhibit other coronaviruses, such as SARS-CoV-1, has been explored with promising results [5].

Early in the 20th century, intense demands for an effective quinine substitute launched the discovery and evaluation of a series of organic compounds (beginning with methylene blue), which led to pamaquine and quinacrine after World War I and ultimately produced chloroquine (CQ) in 1934 [6]. Recognition of the value of chloroquine was delayed, and it was not brought forward until it was reevaluated in the United States and designated the drug of choice against malaria near the end of World War II [7]. Chinese experts recommend that mild, moderate and severe COVID-19 cases (without contraindications to CQ) be treated with 500 milligrams of CQ twice daily for 10 days [8]. Years of safety data show that hydroxychloroquine can cause cardiac ECG QT prolongation and subsequent arrhythmias, including torsades de pointes and can prolong the QT correction (QTc), even when taken as recommended [9].

In a previous study, torsades de pointes was reported in about 1% of patients with QT prolongation after exposure to azithromycin [10].

The proposed chloroquine and azithromycin combination drug therapy for COVID-19 brings along with it some major cardiotoxic concerns. If chloroquine or hydroxychloroquine coadministered with azithromycin end up being the miracle drugs, considering their risks, caution should be taken administering them in certain populations. Of special interest would be those patients that may be infected with COVID-19 and have a known prior history of underlying conditions such as congenital long QT syndromes or electrolyte imbalances particularly potassium and calcium. Furthermore, patients who are currently on medications that equally prolong the QT interval (tricyclic antidepressants, antipsychotics, and even some anti-emetics) who might be infected with COVID-19 are also a population of special interest. Monitoring routine EKGs in these groups of patients is recommended.

Received: May 08, 2020; Accepted: June 01, 2020; Published: June 03, 2020
Copyright: © 2020 Adeyemi O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Ethics Declaration

Competing interests

The author declares no competing interest.

References


